Biogen, AbbVie yank underperforming MS drug Zinbryta after encephalitis reports
admin 2nd March 2018 Uncategorised 0It was a short run, but Biogen and AbbVie’s multiple sclerosis-fighter Zinbryta is coming off markets around the globe. The pair revealed the decision on Friday, citing safety concerns and adding that “it is in the best interest of patients to voluntarily withdraw worldwide marketing authorizations” for the drug, which won FDA approval in May 2016.
More: Biogen, AbbVie yank underperforming MS drug Zinbryta after encephalitis reports
Source: fierce